Immunologic and inflammatory mediators and cognitive decline in Alzheimer's disease

Immunology and Allergy Clinics of North America

Volumn 23, Issue 1, 2003, Pages 103-115

  Ahluwalia, Namanjeet ^a   Vellas, Bruno ^b  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT;

ALZHEIMER DISEASE; BEHAVIOR; BRONCHITIS; CELLULAR IMMUNITY; COGNITION; COGNITIVE DEFECT; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; IMMUNIZATION; IMMUNOREACTIVITY; INDEPENDENCE; INFLAMMATION; MALNUTRITION; MEDIATOR RELEASE; MORBIDITY; MOTOR DYSFUNCTION; PNEUMONIA; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; RISK FACTOR; UPREGULATION;

AGING; ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS; COGNITION DISORDERS; HUMANS;

EID: 0037330873     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8561(02)00048-6     Document Type: Review

References (63)

1. González-Gross M, Marcos A, Pietrzik K. Nutrition and cognitive impairment in the elderly. Br J Nutr 2001;86:313-21.
2. Folstein M. Nutrition and Alzheimer's disease. Nutr Rev 1997;55:23-5.
3. Gillette-Guyonnet S, Nourhashemi F, Andrieu S, et al. Weight loss in Alzheimer disease. Am J Clin Nutr 2000;71(Suppl):637S-42S.
4. Wolf-Klein GP, Silverstone FA. Weight loss in Alzheimer's disease: an international review of the literature. Int Psychogeriatr 1994;6:135-42.
5. Cummings JL, Cole G. Alzheimer disease. JAMA 2002;287:2335-8.
6. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-8.
7. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001;58:397-405.
8. Costa PT, Williams TF, Albert MS, et al. Recognition and initial assessment of Alzheimer's disease and related dementias. Rockville, MD: US Dept Health and Human Services, Agency for Health Care Policy and Research; 1996.
9. Reisberg B, Ferris SH, de Leon MJ, et al. The global deterioration scale (GDS). Psychopharmacol Bull 1988;24:661-3.
10. Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurol 1993; 43:2412-4.
11. Volicier L. Management of severe Alzheimer's disease and end-of-life issues. Clin Geriatr Med 2001;17:377-91.
12. Volicier L, Seltzer B, Rheaume Y, et al. Progression of Alzheimer-type dementia in institutionalized patients: a cross-sectional study. J Appl Gerontol 1987;6:83-94.
13. Selkoe DJ. Amyloid beta-protein and the genetics of Alzheimer's disease. J Biol Chem 1996; 271:18295-8.
14. Holtzman DM, Bales KR, Tenkova T, et al. Apolipoprotein ε isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2000;97:2892-7.
15. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421.
16. Lee Y, Trojanowski JQ. Tau proteins and their significance in the pathobiology of Alzheimer's disease. In: Goate A, Ashall F, editors. Pathobiology of Alzheimer's disease. London: Academic Press; 1995. p. 41-54.
17. Behl C. Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches. Prog Neurobiol 1999;57:301-23.
18. Praticò D, Trojanowski JQ. Inflammatory hypotheses: novel mechanisms of Alzheimer's neurodegneration and new therapeutic targets? Neurobiol Aging 2000;21:441-5.
19. McGeer PL, McGeer EG. Autotoxicity and Alzheimer Disease. Arch Neurol 2000;57:789-90.
20. Marx F, Blasko I, Grubeck-Loebenstein B. Mechanisms of immune regulation in Alzheimer's disease: a viewpoint. Archivum Immunologiae Therapiue Experimentalis 1999;47:205-9.
21. Tenner AJ. Complement in Alzheimer's disease: opportunities for modulating protective and pathogenic events. Neurobiol Aging 2001;22:849-61.
22. Kotwal GJ. Microorganisms and their interaction with the immune system. J Leuk Biol 1997;62: 415-29.
23. Popović M, Caballero-Bleda M, Puelles L, et al. Importance of immunological and inflammatory processes in the pathogenesis and therapy of Alzheimer's disease. Intern J Neuroscience 1998; 95:203-36.
24. Smith MA, Sayre LM, Anderson VE, et al. Cytochemical demonstration of oxidative damage in Alzheimer-disease by immunochemical enhancement of the carbonyl reaction with 2,4-dinitrophenylhydrazine. J Histochem Cytochem 1998;46:731-5.
25. Brod SA. Unregulated inflammation shortens human functional longevity. Inflamm Res 2000;49: 561-70.
26. Schwarz MJ, Chiang S, Müller N, et al. T-helper-1 and T-helper-2 responses in psychiatric disorders. Brain Behav Immun 2001;15:340-70.
27. Wick G, Grubeck-Loebenstein B. Primary and secondary alterations of immune reactivity in the elderly: impact of dietary factors and disease. Immunol Rev 1997; 160:171-84.
28. Meda L, Cassatela MA, Szendrei GI, et al. Activation of microglial cells by β-amyloid protein and interferon γ. Nature 1995;374:647-50.
29. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996; 19:312-8.
30. Banati RB. The immune response in the Alzheimer's disease brain. Biochem Soc Trans 1997;25: 683-5.
31. Frautschy SA, Yang F, Irrizarry M, et al. Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol 1998;152:307-17.
32. Araga S, Kagimoto H, Funamoto K, et al. Reduced natural killer cell activity in patients with dementia of the Alzheimer type. Acta Neurol Scand 1991;84:259-63.
33. Huberman M, Shalit F, Roth-Deri I, et al. Correlation of cytokine secretion by mononuclear cells of Alzheimer patients and their disease stage. J Neuroimmunol 1994;52:147-52.
34. Singh VK, Fudenberg HH, Brown FR. Immunologic dysfunction: simultaneous study of Alzheimer's and older Down's patients. Mech Aging Dev 1987;37:257-64.
35. Song DK, Im YB, Jung JS, et al. Central beta-amyloid peptide-induced peripheral interleukin-6 response in mice. J Neurochem 2001;76:1326-35.
36. Raine CS. Inflammation in Alzheimer's disease: a view from the periphery. Neurobiol Aging 2000;21:437-40.
37. Singh VK, Fudenberg HH. Detection of brain autoantibodies in the serum of patients with Alzheimer's disease but not Down's syndrome. Immunol Lett 1986;12:277-80.
38. Dickson DW, Rogers J. Neruoimmunology of Alzheimer's disease: a conference report. Neurobiol Aging 1992;13:793-8.
39. Schmitt TL, Steger MM, Pavelka M, et al. Interaction of the Alzheimer β-amyloid fragment (25-35) with peripheral blood dendritic cells. Mech Aging Dev 1997;94:223-32.
40. Trieb K, Ransmayr G, Sgonc R, et al. APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's disease. Neurobiol Aging 1996;17:541-7.
41. Marx F, Blasko I, Pavelka M, et al. The possible role of the immune system in Alzheimer's disease. Exp Gerontol 1998;33:871-81.
42. McGeer PL, McGeer EG, Rogers J, et al. Anti-inflammatory drugs and Alzheimer's disease. Lancet 1990;335:1037.
43. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiological studies. Neurol 1996;47: 425-32.
44. Aisen PS, Pasinetti GM. Glucocorticoids in Alzheimer's disease: the story so far. Drugs Aging 1998;12:1-6.
45. Aisen PS. Anti-inflammatory therapy for Alzheimer's disease: implications of the prednisone trial. Acta Neurol Scand 2000; 176(suppl):85-9.
46. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-7.
47. Morgan D, Diamond DM, Gottschall PE, et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000;408:982-5.
48. Janus C, Pearson J, McLaurin J, et al. Aβ immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000;408:979-82.
49. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916-9.
50. Thatte U. AN-1792 (Elan). Curr Opin Investig Drugs 2001;2:663-7.
51. Magaziner J, Tenney JH, DeForge B, et al. Prevalence and characteristics of nursing home acquired infections in the aged. J Am Geriatr Soc 1991;39:1071-8.
52. Fabiszewski KJ, Volicier B, Volicier L. Effect of antibiotic treatment on outcome of fevers in institutionalized Alzheimer patients. JAMA 1990;263:3168-72.
53. Van der Steen JT, Ooms ME, Mehr DR, et al. Severe dementia and adverse outcomes of nursing home-acquired pneumonia: evidence for mediation by functional and pathophysiological decline. J Am Geriatr Soc 2002;50:439-48.
54. Reynish W, Andrieu S, Nourhashemi F, et al. Nutritional factors and Alzheimer's disease. J Gerontol 2001;56:M675-80.
55. Riviere S, Birlouez-Aragon I, Nourhashemi F, et al. Low plasma vitamin C in Alzheimer patients despite an adequate diet. Int J Geriat Psychiatry 1998;13:749-54.
56. Sinclair AJ, Bayer AJ, Johnston J, et al. Altered plasma antioxidant status in subjects with Alzheimer's disease and vascular dementia. Int J Geriat Psychiatry 1998;13:840-5.
57. Spindler AA, Renvall MJ, Nichols JF, et al. Nutritional status of patients with Alzheimer's disease: a 1-year study. J Am Diet Assoc 1996;96:1013-8.
58. 12 and folate in relation to the development of Alzheimer's disease. Neurol 2001;56:1188-94.
59. Chandra RK. Effect of vitamin and trace-element supplementation on immune responses and infection in elderly subjects. Lancet 1992;340:1124-7.
60. High KP. Micronutrient supplementation and immune function in the elderly. Clin Infect Dis 1999;28:717-22.
61. Krause D, Mastro AM, Handte G, et al. Immune function did not decline with aging in apparently healthy, well-nourished women. Mech Ageing Dev 1999;112:43-57.
62. Mazari L, Lesourd BM. Nutritional influences on immune response in healthy aged persons. Mech Ageing Dev 1998;104:25-40.
63. Suskind RA, Tontisirin K. Nutrition, immunity and infection in infants and children. Philadelphia: Lippincott, Williams, & Wilkins; 2001.